Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $37

Benzinga · 11/17/2025 14:55
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $40 to $37.